Skip to main content

In Brief This Week: NeoGenomics, Exosome Diagnostics, Danaher, and More

NEW YORK (360Dx) – NeoGenomics has signed an agreement with Thermo Fisher Scientific to join the Next-Generation Sequencing Companion Dx Center of Excellence Program, also referred to as COEP. NeoGenomics is one of the first laboratories to offer the newly US Food and Drug Administration-approved Oncomine Dx Target Test for non-small cell lung cancer. This methodology allows rapid analysis of samples compared to previously approved testing approaches. NeoGenomics' Pharma Services Division supported the analytical validation of the Oncomine Dx Target Test for submission to the FDA.


Exosome Diagnostics said this week that it has inked an agreement for coverage of ExoDx Prostate IntelliScore (EPI), its prostate cancer risk assessment test, with Three Rivers Provider Network (TRPN) of Chula Vista, California. TRPN — a managed care organization of medical doctors, hospitals, and other healthcare providers — provides healthcare benefits for more than 100 million patients nationwide, and its network consists of more than 1.5 million provider locations and 200 payors, according to Exosome Diagnostics.

Tom McLain, chief operating officer of Exosome Diagnostics, said in a statement that EPI being included on the Centers for Medicare & Medicaid Services Clinical Lab Fee Schedule for 2018 has provided "a sound basis for covering and pricing our test.”


Danaher’s board has approved a regular quarterly dividend of $.14 per share payable on Jan. 26, 2018 to shareholders of record on Dec. 29, 2017.


The US Food and Drug Administration said this week that it has launched a predictive toxicology roadmap to enable advances in toxicity testing. The roadmap includes a six-part framework for integrating predictive toxicology methods into safety and risk assessments, the FDA said.


The US Preventive Services Task Force this week announced the release of its seventh annual report to congress, and highlighted five topics for which it said current evidence is insufficient for it to make a recommendation and for which more research is needed. The task force called for more research into screening for celiac disease; screening for obstructive sleep apnea in adults; screening for gynecologic conditions with pelvic examination; vision screening in children younger than 3; and statin use for the primary prevention of cardiovascular disease in adults age 76 and older.

The report also identifies evidence gaps that prevent it from making recommendations for specific populations. They relate to screening for breast cancer in African American women; screening for prostate cancer in African American men; screening for illicit drug use in children and adolescents; and screening for hearing loss in older adults.


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.